News >

[Fam]-Trastuzumab Deruxtecan Accelerates Through HER2+ Breast Cancer Pipeline

Gina Columbus @ginacolumbusonc
Published: Friday, Mar 29, 2019

Antoine Yver, MD

Antoine Yver, MD
An accelerated filing of a biologics license application (BLA) is planned for [fam-] trastuzumab deruxtecan (DS-8201) as a treatment for patients with HER2-positive metastatic breast cancer previously treated with ado-trastuzumab emtansine (T-DM1; Kadcyla), according to Daiichi Sankyo, the developer of the investigational HER2-targeted antibody-drug conjugate.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication